动态监测创伤脓毒症及非脓毒症血浆中高迁移率族蛋白B1(high-mobility group box-1，HMGB-1)的量，初步探究创伤脓毒症发生发展中部分细胞因子的作用，为临床治疗脓毒症提供依据。

将江苏大学附属武进医院2013年10月－2015年10月收治的28例患者及体检中心健康人群作为研究对象，分为创伤脓毒症组(14例)、创伤非脓毒症组(14例)，正常对照组(20例)。收集确诊时、第1天和第2天患者血浆，用酶联免疫分析法测定HMGB-1的含量。

与对照组比较，创伤非脓毒症组和创伤脓毒症组患者HMGB-1含量均明显升高(P<0.05)；与创伤非脓毒症组各时相点比较，创伤脓毒症组HMGB-1含量明显升高(P<0.05)，但在两组组内各时相点间差异无统计学意义(P>0.05)。

及时监测HMGB-1含量的变化，可更敏感地判断创伤脓毒症的发生，评估其严重程度，为临床治疗提供依据。

To dynamically monitor the content of plasma high-mobility group box-1 (HMGB-1) in patients with trauma and non trauma sepsis and to preliminarily explore the role of some cytokines in development of the disease so as to provide basis for clinical treatment.

A total of 28 trauma patients admitted into Wujin Hospital from October 2013 to October 2015 were enrolled in the study and divided into sepsis group (14 patients) and non-sepsis group (14 patients). The other 20 healthy persons were used as control group. Plasma was collected respectively at the time of diagnosis, the first day and the second day for detecting plasma HMGB-1 by using enzyme league immune analysis method.

Compared with control group, HMGB-1 was significantly increased in sepsis group and non-sepsis group(P<0.05). In each time point, the HMGB-1 concentration was increased more significantly in sepsis group compared with non-sepsis group(P<0.05), but there was no significant difference between each time point within group(P>0.05).

For patients with trauma sepsis, timely monitoring the HMGB-1 change can be more sensitively to judge the occurrence of trauma sepsis, evaluate the severity and hence provide the basis for clinical treatment.